adairАллергология и Иммунология в ПедиатрииAllergology and Immunology in Paediatrics2500-11752712-7958Ассоциация детских аллергологов и иммунологов России10.53529/2500-1175-2023-3-5-15adair-95Research ArticleОБЗОРREVIEWПрактический подход к лечению аллергических заболеванийA practical approach to the treatment of allergic diseaseshttps://orcid.org/0000-0002-7571-5460НовикГ. А.NovikG. A.

Новик Геннадий Айзикович — д. м. н., профессор, заведующий кафедрой детских болезней имени профессора И. М. Воронцова факультета послевузовского и дополнительного профессионального образования

194100, г. Санкт-Петербург, ул. Литовская, д. 2

Gennadiy Aizikovich Novik — Dr. Sci., Рrofessor, Head of I. M. Vorontsov Pediatric diseases Department, Faculty of Postgraduate and Additional Professional Education

2 Litovskaya st., St. Petersburg, 194100

ga_novik@mail.ruhttps://orcid.org/0000-0003-3261-6718ТамразоваО. Б.TamrazovaO. B.

Тамразова Ольга Борисовна — д. м. н., профессор кафедры дерматовенерологии с курсом косметологии факультета непрерывного медицинского образования

117198, г. Москва, ул. Миклухо-Маклая, д. 6

Olga Borisovna Tamrazova — Dr. Sci., Professor of the Department of Dermatovenereology with the course of cosmetology of the Faculty of Continuing Medical Education

6 Miklukho-Maklaya st., Moscow, 117198

tamrazova@mail.ruФГБОУ ВО СПбГПМУ Минздрава РоссииРоссияFSBEI HPE «SPbSPMU» MOH RussiaRussian FederationФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы»РоссияRUDN University named after Patrice LumumbaRussian Federation20230910202303515Copyright © Новик Г.А., Тамразова О.Б., 20232023Новик Г.А., Тамразова О.Б.Novik G.A., Tamrazova O.B.This work is licensed under a Creative Commons Attribution 4.0 License.https://adair.elpub.ru/jour/article/view/95

На сегодняшний день отмечается неуклонный рост аллергических заболеваний, что является тяжким бременем для населения и системы здравоохранения. Высокая распространенность, хроническое течение и выраженное влияние на качество жизни требуют от специалистов рационального подхода к лечению аллергической патологии. С момента своего появления и до настоящего времени антигистаминные препараты широко используются в реальной клинической практике, не теряя своей актуальности. В данной статье рассматривается место антигистаминных препаратов в современной терапии наиболее часто встречающихся аллергических и других гистаминзависимых заболеваний.

To date, there has been a steady increase in allergic diseases, which is a heavy burden on the population and the health care system. The high prevalence, chronic course and pronounced impact on the quality of life require specialists to take a rational approach to the treatment of allergic pathology. From the moment of its appearance to the present, antihistamines have been widely used in real clinical practice, without losing their relevance. This article examines the place of antihistamines in modern therapy of the most common allergic and other histamine-dependent diseases.

антигистаминные препаратыаллергический риниткрапивницаАСИТОРВИдезлоратадинantihistaminesallergic rhinitisurticariaAITARVIdesloratadineReferencesMazur M, Czarnobilska M, Dyga W, Czarnobilska E. Trends in the Epidemiology of Allergic Diseases of the Airways in Children Growing Up in an Urban Agglomeration. J Clin Med. 2022; 11 (8): 2188. Published 2022 Apr 14. https://doi.org/10.3390/jcm11082188.Mazur M, Czarnobilska M, Dyga W, Czarnobilska E. Trends in the Epidemiology of Allergic Diseases of the Airways in Children Growing Up in an Urban Agglomeration. J Clin Med. 2022; 11 (8): 2188. Published 2022 Apr 14. https://doi.org/10.3390/jcm11082188.Fyhrquist N, Werfel T, Bilò MB, Mülleneisen N, Gerth van Wijk R. The roadmap for the Allergology specialty and allergy care in Europe and adjacent countries. An EAACI position paper. Clin Transl Allergy. 2019; 9: 3. Published 2019 Jan 24. https://doi.org/10.1186/s13601-019-0245-z.Fyhrquist N, Werfel T, Bilò MB, Mülleneisen N, Gerth van Wijk R. The roadmap for the Allergology specialty and allergy care in Europe and adjacent countries. An EAACI position paper. Clin Transl Allergy. 2019; 9: 3. Published 2019 Jan 24. https://doi.org/10.1186/s13601-019-0245-z.Sánchez-Borges M, Martin BL, Muraro AM, et al. The importance of allergic disease in public health: an iCAALL statement. World Allergy Organ J. 2018; 11 (1): 8. Published 2018 Apr 27. https://doi.org/10.1186/s40413-018-0187-2.Sánchez-Borges M, Martin BL, Muraro AM, et al. The importance of allergic disease in public health: an iCAALL statement. World Allergy Organ J. 2018; 11 (1): 8. Published 2018 Apr 27. https://doi.org/10.1186/s40413-018-0187-2.Mahdy AM, Webster NR. Histamine and antihistamines. Anaesthesia & Intensive Care Medicine. 2011; 12 (7): 324–329. https://doi.org/10.1016/j.mpaic.2011.04.012.Mahdy AM, Webster NR. Histamine and antihistamines. Anaesthesia & Intensive Care Medicine. 2011; 12 (7): 324–329. https://doi.org/10.1016/j.mpaic.2011.04.012.Tiligada E, Ennis M. Histamine pharmacology: from Sir Henry Dale to the 21st century. Br J Pharmacol. 2020 Feb; 177 (3): 469–489. https://doi.org/10.1111/bph.14524. Epub 2018 Dec 2. PMID: 30341770; PMCID: PMC7012941.Tiligada E, Ennis M. Histamine pharmacology: from Sir Henry Dale to the 21st century. Br J Pharmacol. 2020 Feb; 177 (3): 469–489. https://doi.org/10.1111/bph.14524. Epub 2018 Dec 2. PMID: 30341770; PMCID: PMC7012941.Meltzer EO. Allergic Rhinitis: Burden of Illness, Quality of Life, Comorbidities, and Control. Immunol Allergy Clin North Am. 2016 May; 36 (2): 235–248. https://doi.org/10.1016/j.iac.2015.12.002. Epub 2016 Mar 4. PMID: 27083099.Meltzer EO. Allergic Rhinitis: Burden of Illness, Quality of Life, Comorbidities, and Control. Immunol Allergy Clin North Am. 2016 May; 36 (2): 235–248. https://doi.org/10.1016/j.iac.2015.12.002. Epub 2016 Mar 4. PMID: 27083099.GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16; 390 (10100): 1211–1259. https://doi.org/10.1016/S0140-6736(17)32154-2.GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16; 390 (10100): 1211–1259. https://doi.org/10.1016/S0140-6736(17)32154-2.Wise SK, Damask C, Roland LT et.al. International consensus statement on allergy and rhinology: Allergic rhinitis — 2023. Int Forum Allergy Rhinol. 2023 Apr; 13 (4): 293–859. https://doi.org/10.1002/alr.23090. Epub 2023 Mar 6. PMID: 36878860.Wise SK, Damask C, Roland LT et.al. International consensus statement on allergy and rhinology: Allergic rhinitis — 2023. Int Forum Allergy Rhinol. 2023 Apr; 13 (4): 293–859. https://doi.org/10.1002/alr.23090. Epub 2023 Mar 6. PMID: 36878860.Linneberg A, Dam Petersen K, Hahn-Pedersen J et. al. Burden of allergic respiratory disease: a systematic review. Clin Mol Allergy. 2016 Sep 28; 14: 12. doi: 10.1186/s12948-016-0049-9. PMID: 27708552; PMCID: PMC5041537.Linneberg A, Dam Petersen K, Hahn-Pedersen J et. al. Burden of allergic respiratory disease: a systematic review. Clin Mol Allergy. 2016 Sep 28; 14: 12. doi: 10.1186/s12948-016-0049-9. PMID: 27708552; PMCID: PMC5041537.Izuhara Y, Matsumoto H, Nagasaki T et. al. Nagahama Study Group. Mouth breathing, another risk factor for asthma: the Nagahama Study. Allergy. 2016 Jul; 71 (7): 1031–1036. https://doi.org/10.1111/all.12885. Epub 2016 Apr 1. PMID: 26991116.Izuhara Y, Matsumoto H, Nagasaki T et. al. Nagahama Study Group. Mouth breathing, another risk factor for asthma: the Nagahama Study. Allergy. 2016 Jul; 71 (7): 1031–1036. https://doi.org/10.1111/all.12885. Epub 2016 Apr 1. PMID: 26991116.Клинические рекомендации «Аллергический ринит». 2020. Одобрены Научно-практическим советом МЗ РФ. Протокол № 38/2-3-4 от 16.10.2020. Разработчики КР: Российская ассоциация аллергологов и клинических иммунологов, Национальная медицинская ассоциация оториноларингологов, Союз педиатров России.Klinicheskie rekomendacii «Allergicheskij rinit». 2020. Odobreny Nauchno-prakticheskim sovetom MZ RF. Protokol № 38/2-3-4 ot 16.10.2020. Razrabotchiki KR: Rossijskaya associaciya allergologov i klinicheskih immunologov, Nacional’naya medicinskaya associaciya otorinolaringologov, Soyuz pediatrov Rossii. (In Russ)].Siddiqui ZA, Walker A, Pirwani MM, et al. Allergic rhinitis: diagnosis and management. Br J Hosp Med (Lond). 2022 Feb 2; 83 (2): 1–9. https://doi.org/10.12968/hmed.2021.0570. Epub 2022 Feb 23. PMID: 35243888.Siddiqui ZA, Walker A, Pirwani MM, et al. Allergic rhinitis: diagnosis and management. Br J Hosp Med (Lond). 2022 Feb 2; 83 (2): 1–9. https://doi.org/10.12968/hmed.2021.0570. Epub 2022 Feb 23. PMID: 35243888.Breiteneder H, Peng YQ, Agache I et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy. 2020 Dec; 75 (12): 3039–3068. https://doi.org/10.1111/all.14582. Epub 2020 Sep 30. PMID: 32893900; PMCID: PMC7756301.Breiteneder H, Peng YQ, Agache I et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy. 2020 Dec; 75 (12): 3039–3068. https://doi.org/10.1111/all.14582. Epub 2020 Sep 30. PMID: 32893900; PMCID: PMC7756301.Okubo K, Kurono Y, Ichimura K et al; Japanese Society of Allergology. Japanese guidelines for allergic rhinitis 2020. Allergol Int. 2020 Jul; 69 (3): 331–345. https://doi.org/10.1016/j.alit.2020.04.001. Epub 2020 May 27. PMID: 32473790.Okubo K, Kurono Y, Ichimura K et al; Japanese Society of Allergology. Japanese guidelines for allergic rhinitis 2020. Allergol Int. 2020 Jul; 69 (3): 331–345. https://doi.org/10.1016/j.alit.2020.04.001. Epub 2020 May 27. PMID: 32473790.Kawauchi H, Yanai K, Wang DY et al. Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties. Int J Mol Sci. 2019; 20 (1): 213. Published 2019 Jan 8. https://doi.org/10.3390/ijms20010213.Kawauchi H, Yanai K, Wang DY et al. Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties. Int J Mol Sci. 2019; 20 (1): 213. Published 2019 Jan 8. https://doi.org/10.3390/ijms20010213.Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011 Dec; 128 (6): 1139–1150.e4. https://doi.org/10.1016/j.jaci.2011.09.005. Epub 2011 Oct 27. PMID: 22035879.Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011 Dec; 128 (6): 1139–1150.e4. https://doi.org/10.1016/j.jaci.2011.09.005. Epub 2011 Oct 27. PMID: 22035879.Bousquet J, Khaltaev N, Cruz AA et al; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr; 63 Suppl 86: 8–160. https://doi.org/10.1111/j.1398-9995.2007.01620.x. PMID: 18331513.Bousquet J, Khaltaev N, Cruz AA et al; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr; 63 Suppl 86: 8–160. https://doi.org/10.1111/j.1398-9995.2007.01620.x. PMID: 18331513.Du Buske LM. Pharmacology of desloratadine: Special characteristics Clinical Drug Investigation. 2002; 22 (12): 1–11.Du Buske LM. Pharmacology of desloratadine: Special characteristics Clinical Drug Investigation. 2002; 22 (12): 1–11.Okano M, Fujieda S, Gotoh M et al. Executive summary: Japanese guidelines for allergic rhinitis 2020. Allergol Int. 2023 Jan; 72 (1): 41–53. https://doi.org/10.1016/j.alit.2022.11.003.Okano M, Fujieda S, Gotoh M et al. Executive summary: Japanese guidelines for allergic rhinitis 2020. Allergol Int. 2023 Jan; 72 (1): 41–53. https://doi.org/10.1016/j.alit.2022.11.003.Baena-Cagnani CE, Canonica GW, Zaky Helal M, et al; ISMAR Study Group. The international survey on the management of allergic rhinitis by physicians and patients (ISMAR). World Allergy Organ J. 2015 Mar 20; 8 (1): 10. https://doi.org/10.1186/s40413-015-0057-0. PMID: 25977744; PMCID: PMC4367873.Baena-Cagnani CE, Canonica GW, Zaky Helal M, et al; ISMAR Study Group. The international survey on the management of allergic rhinitis by physicians and patients (ISMAR). World Allergy Organ J. 2015 Mar 20; 8 (1): 10. https://doi.org/10.1186/s40413-015-0057-0. PMID: 25977744; PMCID: PMC4367873.Bjermer L, Westman M, Holmström M, Wickman MC. The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option. Allergy Asthma Clin Immunol. 2019 Apr 16; 15: 24. https://doi.org/10.1186/s13223-018-0314-1. PMID: 31015846; PMCID: PMC6469109.Bjermer L, Westman M, Holmström M, Wickman MC. The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option. Allergy Asthma Clin Immunol. 2019 Apr 16; 15: 24. https://doi.org/10.1186/s13223-018-0314-1. PMID: 31015846; PMCID: PMC6469109.Canonica GW, Tarantini F, Compalati E, Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy. 2007 Apr; 62 (4): 359–366. https://doi.org/10.1111/j.13989995.2006.01277.x. PMID: 17362245.Canonica GW, Tarantini F, Compalati E, Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy. 2007 Apr; 62 (4): 359–366. https://doi.org/10.1111/j.13989995.2006.01277.x. PMID: 17362245.Bachert C, Maurer M. Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin Drug Investig. 2010; 30 (2): 109–122. https://doi.org/10.2165/11530930000000000-00000. PMID: 20067329.Bachert C, Maurer M. Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin Drug Investig. 2010; 30 (2): 109–122. https://doi.org/10.2165/11530930000000000-00000. PMID: 20067329.Bousquet J, Bachert C, Canonica GW, et al; ACCEPT-1 study group. Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy. 2009 Oct; 64 (10): 1516–1523. https://doi.org/10.1111/j.1398-9995.2009.02115.x.Bousquet J, Bachert C, Canonica GW, et al; ACCEPT-1 study group. Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy. 2009 Oct; 64 (10): 1516–1523. https://doi.org/10.1111/j.1398-9995.2009.02115.x.Bousquet J, Bachert C, Canonica GW, et al; ACCEPT-2 Study Group. Efficacy of desloratadine in persistent allergic rhinitis — a GA²LEN study. Int Arch Allergy Immunol. 2010; 153 (4): 395–402. https://doi.org/10.1159/000316351.Bousquet J, Bachert C, Canonica GW, et al; ACCEPT-2 Study Group. Efficacy of desloratadine in persistent allergic rhinitis — a GA²LEN study. Int Arch Allergy Immunol. 2010; 153 (4): 395–402. https://doi.org/10.1159/000316351.Villa E, Rogkakou A, Garelli V, Canonica GW. Review of Desloratadine Data Using the ARIA Guidelines. World Allergy Organ J. 2012 Jan; 5 Suppl 1: S6–S13. https://doi.org/10.1097/WOX.0b013e318216b438. PMID: 23282891.Villa E, Rogkakou A, Garelli V, Canonica GW. Review of Desloratadine Data Using the ARIA Guidelines. World Allergy Organ J. 2012 Jan; 5 Suppl 1: S6–S13. https://doi.org/10.1097/WOX.0b013e318216b438. PMID: 23282891.Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022 Sep 15; 8 (1): 61. https://doi.org/10.1038/s41572-022-00389-z. PMID: 36109590.Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022 Sep 15; 8 (1): 61. https://doi.org/10.1038/s41572-022-00389-z. PMID: 36109590.Schaefer P. Acute and Chronic Urticaria: Evaluation and Treatment. Am Fam Physician. 2017 Jun 1; 95 (11): 717–724. PMID: 28671445.Schaefer P. Acute and Chronic Urticaria: Evaluation and Treatment. Am Fam Physician. 2017 Jun 1; 95 (11): 717–724. PMID: 28671445.Zuberbier T, Aberer W, Asero R, et al; European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2)LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014 Jul; 69 (7): 868–887. https://doi.org/10.1111/all.12313. Epub 2014 Apr 30. PMID: 24785199.Zuberbier T, Aberer W, Asero R, et al; European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2)LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014 Jul; 69 (7): 868–887. https://doi.org/10.1111/all.12313. Epub 2014 Apr 30. PMID: 24785199.Федеральные клинические рекомендации РААКИ по диагностике и лечению крапивницы. Утверждено президиумом РААКИ 25.12.2015. Российский Аллергологический Журнал. 2016; 1: 37–45.Federal’nye klinicheskie rekomendacii RAAKI po diagnostike i lecheniyu krapivnicy. Utverzhdeno prezidiumom RAAKI 25.12.2015. Rossijskij Allergologicheskij ZHurnal. 2016; 1: 37–45. (In Russ)]Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J Allergy Clin Immunol. 2017 Jun; 139 (6): 1772–1781.e1. https://doi.org/10.1016/j.jaci.2016.08.050. Epub 2016 Oct 21. PMID: 27777182.Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J Allergy Clin Immunol. 2017 Jun; 139 (6): 1772–1781.e1. https://doi.org/10.1016/j.jaci.2016.08.050. Epub 2016 Oct 21. PMID: 27777182.Schocket AL. Chronic urticaria: pathophysiology and etiology, or the what and why. Allergy Asthma Proc. 2006 Mar-Apr; 27 (2): 90–95. PMID: 16724623.Schocket AL. Chronic urticaria: pathophysiology and etiology, or the what and why. Allergy Asthma Proc. 2006 Mar-Apr; 27 (2): 90–95. PMID: 16724623.Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al.The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022 Mar; 77 (3): 734–766. https://doi.org/10.1111/all.15090. Epub 2021 Oct 20. PMID: 34536239.Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al.The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022 Mar; 77 (3): 734–766. https://doi.org/10.1111/all.15090. Epub 2021 Oct 20. PMID: 34536239.Augustin M, Ehrle S. Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. J Eur Acad Dermatol Venereol. 2009 Mar; 23 (3): 292–299. https://doi.org/10.1111/j.1468-3083.2008.03034.x. Erratum in: J Eur Acad Dermatol Venereol. 2009 Mar; 23 (3): 498. PMID: 19438819.Augustin M, Ehrle S. Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. J Eur Acad Dermatol Venereol. 2009 Mar; 23 (3): 292–299. https://doi.org/10.1111/j.1468-3083.2008.03034.x. Erratum in: J Eur Acad Dermatol Venereol. 2009 Mar; 23 (3): 498. PMID: 19438819.Mosam A, Todd G. Global epidemiology and disparities in atopic dermatitis. Br J Dermatol. 2023 May 24; 188 (6): 726–737. https://doi.org/10.1093/bjd/ljad042. PMID: 36881991.Mosam A, Todd G. Global epidemiology and disparities in atopic dermatitis. Br J Dermatol. 2023 May 24; 188 (6): 726–737. https://doi.org/10.1093/bjd/ljad042. PMID: 36881991.Yosipovitch G, Misery L, Proksch E et al. Skin Barrier Damage and Itch: Review of Mechanisms, Topical Management and Future Directions. Acta Derm Venereol. 2019 Dec 1; 99 (13): 1201–1209. https://doi.org/10.2340/00015555-3296. PMID: 31454051.Yosipovitch G, Misery L, Proksch E et al. Skin Barrier Damage and Itch: Review of Mechanisms, Topical Management and Future Directions. Acta Derm Venereol. 2019 Dec 1; 99 (13): 1201–1209. https://doi.org/10.2340/00015555-3296. PMID: 31454051.Lee JH, Kim JE, Park GH et al. Consensus Update for Systemic Treatment of Atopic Dermatitis. Ann Dermatol. 2021 Dec; 33 (6): 497–514. https://doi.org/10.5021/ad.2021.33.6.497. Epub 2021 Nov 4. PMID: 34858001; PMCID: PMC8577915.Lee JH, Kim JE, Park GH et al. Consensus Update for Systemic Treatment of Atopic Dermatitis. Ann Dermatol. 2021 Dec; 33 (6): 497–514. https://doi.org/10.5021/ad.2021.33.6.497. Epub 2021 Nov 4. PMID: 34858001; PMCID: PMC8577915.Клинические рекомендации «Атопический дерматит». 2021. Одобрены Научно-практическим советом МЗ РФ. Разработчики КР: Российское общество дерматовенерологов и косметологов, Российская ассоциация аллергологов и клинических иммунологов, Союз педиатров России.Klinicheskie rekomendacii «Atopicheskij dermatit». 2021. Odobreny Nauchno-prakticheskim sovetom MZ RF. Razrabotchiki KR: Rossijskoe obshchestvo dermatovenerologov i kosmetologov, Rossijskaya associaciya allergologov i klinicheskih immunologov, Soyuz pediatrov Rossii. (In Russ)].Eichenfield LF, Ahluwalia J, Waldman A, et al. Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017 Apr; 139 (4S): S49–S57. https://doi.org/10.1016/j.jaci.2017.01.009. PMID: 28390477.Eichenfield LF, Ahluwalia J, Waldman A, et al. Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017 Apr; 139 (4S): S49–S57. https://doi.org/10.1016/j.jaci.2017.01.009. PMID: 28390477.Warren CM, Jiang J, Gupta RS. Epidemiology and Burden of Food Allergy. Curr Allergy Asthma Rep. 2020 Feb 14; 20 (2): 6. https://doi.org/10.1007/s11882-020-0898-7. PMID: 32067114.Warren CM, Jiang J, Gupta RS. Epidemiology and Burden of Food Allergy. Curr Allergy Asthma Rep. 2020 Feb 14; 20 (2): 6. https://doi.org/10.1007/s11882-020-0898-7. PMID: 32067114.Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Historical document. Ann Allergy. 1960 Apr; 18: 427–434. PMID: 13824740.Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Historical document. Ann Allergy. 1960 Apr; 18: 427–434. PMID: 13824740.Cox LS, Larenas Linnemann D, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006 May; 117 (5): 1021–1035. https://doi.org/10.1016/j.jaci.2006.02.040. PMID: 16675328.Cox LS, Larenas Linnemann D, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006 May; 117 (5): 1021–1035. https://doi.org/10.1016/j.jaci.2006.02.040. PMID: 16675328.James C, Bernstein DI. Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol. 2017; 17 (1): 55–59. doi:10.1097/ACI.0000000000000335.James C, Bernstein DI. Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol. 2017; 17 (1): 55–59. doi:10.1097/ACI.0000000000000335.Федеральные клинические рекомендации по проведению аллерген-специфической иммунотерапии. 2013. Разработчик КР: Российская ассоциация аллергологов и клинических иммунологов. Утверждено президиумом РААКИ 23.12.2013.Federal’nye klinicheskie rekomendacii po provedeniyu allergen-specificheskoj immunoterapii. 2013. Razrabotchik KR: Rossijskaya associaciya allergologov i klinicheskih immunologov. Utverzhdeno prezidiumom RAAKI 23.12.2013. (In Russ)].Jin X, Ren J, Li R, Gao Y, et al. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. Clinical Medicine. 2021 Jun 28; 37: 100986. https://doi.org/10.1016/j.eclinm.2021.100986. PMID: 34386754; PMCID: PMC8343248.Jin X, Ren J, Li R, Gao Y, et al. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. Clinical Medicine. 2021 Jun 28; 37: 100986. https://doi.org/10.1016/j.eclinm.2021.100986. PMID: 34386754; PMCID: PMC8343248.Breiteneder H, Peng YQ, Agache I, et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy. 2020 Dec; 75 (12): 3039–3068. https://doi.org/10.1111/all.14582. Epub 2020 Sep 30. PMID: 32893900; PMCID: PMC7756301.Breiteneder H, Peng YQ, Agache I, et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy. 2020 Dec; 75 (12): 3039–3068. https://doi.org/10.1111/all.14582. Epub 2020 Sep 30. PMID: 32893900; PMCID: PMC7756301.DeGeorge KC, Ring DJ, Dalrymple SN. Treatment of the Common Cold. Am Fam Physician. 2019 Sep 1; 100 (5): 281–289. PMID: 31478634.DeGeorge KC, Ring DJ, Dalrymple SN. Treatment of the Common Cold. Am Fam Physician. 2019 Sep 1; 100 (5): 281–289. PMID: 31478634.Damm M, Jayme KP, Klimek L. Recurrent otitis media with effusion in childhood: when should an otolaryngologist consider an allergic etiology? HNO. 2013 Oct; 61 (10): 843–848. German. https://doi.org/10.1007/s00106-013-2700-9. PMID: 23913190.Damm M, Jayme KP, Klimek L. Recurrent otitis media with effusion in childhood: when should an otolaryngologist consider an allergic etiology? HNO. 2013 Oct; 61 (10): 843–848. German. https://doi.org/10.1007/s00106-013-2700-9. PMID: 23913190.van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 2022 Jan 19; 39 (1): 159–167. https://doi.org/10.1093/fampra/cmab076. PMID: 34268556; PMCID: PMC8414057.van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 2022 Jan 19; 39 (1): 159–167. https://doi.org/10.1093/fampra/cmab076. PMID: 34268556; PMCID: PMC8414057.Glynne P, Tahmasebi N, Gant V, Gupta R. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J Investig Med. 2022 Jan; 70 (1): 61–67.Glynne P, Tahmasebi N, Gant V, Gupta R. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J Investig Med. 2022 Jan; 70 (1): 61–67.Anthes JC, Gilchrest H, Richard C, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol. 2002 Aug 9; 449 (3): 229–237. https://doi.org/10.1016/s0014-2999(02)02049-6. PMID: 12167464.Anthes JC, Gilchrest H, Richard C, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol. 2002 Aug 9; 449 (3): 229–237. https://doi.org/10.1016/s0014-2999(02)02049-6. PMID: 12167464.Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy. 2001 Sep; 31 (9): 1369–1377. https://doi.org/10.1046/j.13652222.2001.01130.x. PMID: 11591186.Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy. 2001 Sep; 31 (9): 1369–1377. https://doi.org/10.1046/j.13652222.2001.01130.x. PMID: 11591186.Weller K, Maurer M. Desloratadine inhibits human skin mast cell activation and histamine release. J Invest Dermatol. 2009 Nov; 129 (11): 2723–2726. https://doi.org/10.1038/jid.2009.134. Epub 2009 Jun 11. PMID: 19516262.Weller K, Maurer M. Desloratadine inhibits human skin mast cell activation and histamine release. J Invest Dermatol. 2009 Nov; 129 (11): 2723–2726. https://doi.org/10.1038/jid.2009.134. Epub 2009 Jun 11. PMID: 19516262.Canonica GW, Blaiss M. Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organ J. 2011 Feb; 4 (2): 47–53. doi: 10.1097/WOX. 0b013e3182093e19.Canonica GW, Blaiss M. Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organ J. 2011 Feb; 4 (2): 47–53. doi: 10.1097/WOX. 0b013e3182093e19.Инструкция по применению Эриус® сироп. Регистрационный номер: П № 014704/01. 04.03.2019.Instrukciya po primeneniyu Erius® syrup. Registracionnyj nomer: P № 014704/01. 04.03.2019. (In Russ)].Bloom M, Staudinger H, Herron J. Safety of desloratadine syrup in children. Curr Med Res Opin. 2004 Dec; 20 (12): 1959–1965. https://doi.org/10.1185/030079904x14148. PMID: 15701213.Bloom M, Staudinger H, Herron J. Safety of desloratadine syrup in children. Curr Med Res Opin. 2004 Dec; 20 (12): 1959–1965. https://doi.org/10.1185/030079904x14148. PMID: 15701213.Gupta SK, Kantesaria B, Banfield C, Wang Z. Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. Br J Clin Pharmacol. 2007 Aug; 64 (2): 174–184. doi: 10.1111/j.13652125.2007.02859.x. Epub 2007 Feb 23. PMID: 17324243; PMCID: PMC2000635.Gupta SK, Kantesaria B, Banfield C, Wang Z. Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. Br J Clin Pharmacol. 2007 Aug; 64 (2): 174–184. doi: 10.1111/j.13652125.2007.02859.x. Epub 2007 Feb 23. PMID: 17324243; PMCID: PMC2000635.Prenner B, Ballona R, Bueso A et al. Safety of desloratadine syrup in children six months to younger than 2 years of age: a randomized, double-blinded, placebo-controlled study. Ped Asthma Allergy Immunol. 2006; 19 (2): 91–99.Prenner B, Ballona R, Bueso A et al. Safety of desloratadine syrup in children six months to younger than 2 years of age: a randomized, double-blinded, placebo-controlled study. Ped Asthma Allergy Immunol. 2006; 19 (2): 91–99.Shah KH., & Verma R J. (2011). Butyl p-hydroxybenzoic acid induces oxidative stress in mice liver — an in vivo study. Acta poloniae pharmaceutica. 2011; 68 (6): 875–879.Shah KH., & Verma R J. (2011). Butyl p-hydroxybenzoic acid induces oxidative stress in mice liver — an in vivo study. Acta poloniae pharmaceutica. 2011; 68 (6): 875–879.Vo TT, Yoo YM, Choi KC, & Jeung EB. (2010). Potential estrogenic effect(s) of parabens at the prepubertal stage of a postnatal female rat model. Reproductive toxicology (Elmsford, N.Y.). 2010; 29 (3): 306–316. https://doi.org/10.1016/j.reprotox.2010.01.013.Vo TT, Yoo YM, Choi KC, & Jeung EB. (2010). Potential estrogenic effect(s) of parabens at the prepubertal stage of a postnatal female rat model. Reproductive toxicology (Elmsford, N.Y.). 2010; 29 (3): 306–316. https://doi.org/10.1016/j.reprotox.2010.01.013.

The authors declare that there are no conflicts of interest present.